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http://dx.doi.org/10.1016/j.jmii.2013The infection rate of arteriovenous (AV) grafts is high, but fungal etiology is rare. Only five
cases of graft infection due to Candida albicans (C. albicans) or C. tropicalis have been
described in the literature. Herein, we report the first case of AV graft infection caused by
C. glabrata. A 60-year-old woman on maintenance hemodialysis for end-stage renal disease
was admitted because of intermittent fever, for 10 days. Upon physical examination, tender-
ness over the AV graft site was noticed. Blood culture yielded C. glabrata and her clinical
symptoms improved after she was treated with micafungin for 1 month. However, C. glabrata
candidemia reoccurred 5 weeks later. Cure was achieved after removal of the AV graft and an-
idulafungin treatment. Pus was observed in the removed graft, from which C. glabrata was iso-
lated. The outcome of our case and patients from the literature review suggest that removal of
the infected graft is important for treatment success of AV graft Candida infection.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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In the hemodialysis population, infection is second to
cardiovascular disease in causing morbidity and mortality.1
The infection rates of permanent hemodialysis vascular
access [including arteriovenous (AV) fistula andished by Elsevier Taiwan LLC. All rights reserved.
Candida glabrata arteriovenous graft infection 301polytetrafluoroethylene (PTFE) AV graft] range from 11% to
35%.2 The most common pathogens in AV graft infection are
Staphylococcus aureus (S. aureus), coagulase-negative
Staphylococcus, Gram-negative rods, and Enterococci.3
Fungal infections are rare and the optimal treatment
strategy was not defined. Only five cases have been re-
ported to have Candida AV graft infection and the causative
pathogens were C. albicans and C. tropicalis.4e6 We re-
ported the first case of AV graft infection due to C. glabrata
and performed a review of cases of Candida AV graft
infection in the literature.Figure 1. Erythema over the AV graft site.Case report
A 60-year-old Taiwanese woman receiving regular hemodi-
alysis was admitted to hospital for fever without an obvious
infection source. She had a history of end-stage renal dis-
ease (ESRD), type 2 diabetes mellitus, hypertension,
congestive heart failure NYHA II/VI, and gastric ulcer. She
had received hemodialysis with the right forearm native AV
fistula before. Because of occlusion of the native fistula, it
was removed in December 2008. Hemodialysis was then
performed via the left forearm PTFE AV graft, which was
removed because of graft infection caused by methicillin-
resistant S. aureus (MRSA) in December 2009. A new right
forearm AV graft was then created in March 2010.
Five months after the right forearm graft creation, she
presented to the hospital with intermittent fever, accom-
panied by chills for 10 days, especially after hemodialysis.
On physical examination, there was no local heat, swelling,
erythematous change, or drainage over the graft site, but
mild tenderness was noticed. She had clear breath sounds
and no cardiac murmur, abdominal pain, or lymphadenop-
athy. Her white blood cell count was 3700/mm3 with 73%
neutrophils and her C-reactive protein (CRP) level was
10.8 mg/L. We collected three sets of blood cultures on the
day of admission and gave intravenous vancomycin for
suspicion of AV graft infection, due to her previous history
of MRSA graft infection. Her fever persisted after a 5-day
course of vancomycin treatment. All three blood cultures
yielded C. glabrata. The patient had not received any
antifungal agent for at least 1 year before admission. We
treated the patient with intravenous micafungin 100 mg/
day for C. glabrata candidemia and she became afebrile 5
days after the initiation of micafungin. A repeat blood
culture after 6 days of micafungin treatment revealed no
growth of C. glabrata. Transesophageal echocardiogram
(TEE) was performed for candidemia and revealed no
visible intracardiac vegetation. She was treated with
micafungin for 1 month, to attain a normal-range CRP level
and then discharged.
Five weeks later, fever recurred and she had tenderness
and swelling with erythematous changes over the graft site
(Fig. 1). She was admitted again and received micafungin
100 mg/day. C. glabrata was isolated from blood cultures
again and the susceptibility testing revealed susceptible
dose dependency (SDD) to fluconazole and itraconazole
(MICs Z 16 mg/mL and 0.25 mg/mL, respectively) by the
method of ATB FUNGUS 3 (bioMe´rieux, Marcy-l’Etoile,
France).7 The isolate was susceptible to 5-flucytosine,
voriconazole, and amphotericin B. Her fever persisted after14 days of micafungin treatment. The susceptibility results
for echinocandins were not obtained until 2013, when a
commercial system (Sensititre YeastOne, Trek Diagnostic
Systems, East Grinstead, UK) based on the microbroth
dilution method was available in the hospital. Besides the
same susceptibility results being obtained for fluconazole,
itraconazole, voriconazole, 5-flucytosine, and amphoter-
icin B as the ATB FUNGUS 3 kit revealed, the isolate was
susceptible to caspofungin, micafungin and anidulafungin
(MICs Z 1 mg/mL, 2 mg/mL, and 2 mg/mL, respectively).
TEE was performed again and still showed no evidence of
intracardiac vegetation, whereas an ophthalmologist
consultation suggested neither Roth’s spots nor endoph-
thalmitis, and infective endocarditis were excluded. Ten
sets of blood cultures were positive for C. glabrata during
the 36 day follow-up period. The patient had fever inter-
mittently during the period, but she hesitated in undergo-
ing surgery for removal of the AV graft, despite the fact
that the AV graft was considered as the only infection
focus. Removal of the AV graft was finally performed under
the patient’s consent and pus in the lumen of the AV graft
was observed. The culture of the removed graft also yiel-
ded C. glabrata. Anidulafungin 100 mg/day was started 3
days before removal of the AV graft and continued for a
month. The antifungal treatment was discontinued after
her CRP level fell to within the normal range. After the
graft removal, the patient became afebrile and the subse-
quent blood cultures documented eradication. No further
C. glabrata infection occurred within 1 year of follow-up.
Discussion
The characteristics of five other cases of AV graft Candida
infection in literature and this case are summarized in
Table 1. All six cases used PTFE graft when AV graft Candida
infection occurred. Use of PTFE grafts and graft revisions
had been identified as risk factors for vascular access site
infection.8 The use of PTFE grafts resulted in the absence of
the endogenous cellular components which help to combat
infection in native vessels.9 Although the infection rate of
AV grafts due to bacteria is higher than the rate of native AV
Table 1 Clinical characteristics of patients with arteriovenous (AV) graft Candida infection
Case YearRef Age/sex Clinical presentation Culture site and
organism
Underlying condition
that caused
hemodialysis
Removal of
AV graft
Antifungal
therapy
Outcome
1 19874 67/M Draining fistula Wound: C. albicans,
E. faecalis
No data Yes Amphotericin B Died (autopsy result:
no Candida infection)
2 19918 65/M Fever, hypotension Blood: C. albicans Acute tubular
necrosis
Yes Amphotericin B and
5-flucytosine
Died (persistent
candidemia)
3 19938 52/F Erythema, draining
fistula
Wound and blood:
C. tropicalis,
C. albicans
Polycystic kidney
disease
Yes Amphotericin B Cured
4 19948 54/M Draining ulcer,
non-functional
fistula
Hematoma and blood:
C. tropicalis
Focal sclerosing
glomerulonephritis
thrombectomy
and partial
fistula removal
initially
Fluconazole Relapsed
Yes Fluconazole Cured
5 20087 63/F Knee swelling
and pain, fever
Graft, synovial
fluid and blood:
C. albicans
Hypertension No Fluconazole Relapsed
Yes Fluconazole Cured
6 2011
[This study]
60/F Fever, tenderness Graft and blood:
C. glabrata
DM, hypertension No Micafungin Relapsed
Fever, tenderness
Erythema
Yes Anidulafungin Cured
C. Z Candida; E. Z Enterococcus.
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Candida glabrata arteriovenous graft infection 303fistula infection,10 there is no report to compare the
Candida infection rates between AV graft and native fistula
cases. Our results revealed that all AV graft Candida
infection cases used PTFE grafts.
The clinical manifestations of six AV graft Candida
infection cases varied. Four of the six cases (Nos. 1, 3, 4,
and 6) had signs and symptoms of AV graft infection, which
included drainage found in AV graft sites in three patients
(Nos. 1, 3, and 4), erythematous change over graft sites in
two patients (Nos. 3 and 6), and a draining ulcer over a
nonfunctional graft (No. 4). Only one case had a nonfunc-
tional graft when candidemia occurred. Moreover, one case
presented with septic shock, but had no obvious local
infection signs. The above indicates that localized symp-
toms or signs of infection over the graft site vary and can be
absent in Candida AV graft infection. In contrast, fever,
pain, tenderness, redness, diffuse, or localized swelling,
and serous or purulent discharge over the graft site are
common in those having bacterial infection of AV access.3
The diagnosis of AV graft Candida infection is mainly
confirmed by the culture of the graft. Five of the six
Candida graft infection cases had Candida species isolated
from blood cultures (Table 1). Blood culture reveals a
valuable tool to identify the causative pathogen for such
cases. All of the six patients received antecedent antibac-
terial agents, which indicates that fungal etiology is not
commonly considered and is not empirically treated in
clinical practice. Our report alerts clinicians to consider AV
access site as the possible source of candidemia.
Without complete AV graft removal, three patients (Nos.
4, 5, and 6) had temporary clinical improvement with the
initial antifungal treatment. All of the three cases had
recurrent candidemia. Cure was only achieved after entire
AV graft removal in combination with antifungal therapy.
Among three patients (Nos. 1, 2, and 3) who received
antifungal therapy and graft removal, one attained clinical
success, but two had a fatal outcome. Of the two mortality
cases, only one case died of persistent candidemia. He was
a liver transplant recipient under immunosuppressant
therapy and was the only case with septic shock as the
initial presentation (No. 2). The other one died of his un-
derlying conditions and lacked evidence of disseminated
Candida infection by postmortem autopsy (No. 1). With AV
graft removal and antifungal treatment, mortality due to
Candida infection only occurred in one liver transplant
recipient presenting with septic shock.
For AV graft infection related bacteremia, surgical
exploration and removal of the infected graft material,
combined with antibiotic therapy, are often necessary for
complete resolution.11 However, no treatment guidelines
have been proposed for candidemia caused by AV graft
Candida infection. In the first episode of C. glabrata can-
didemia of our case, the antifungal treatment stopped
when the CRP level was within the normal range, however,
recurrence occurred without removal of the AV graft.
Procalcitonin (PCT) has been described as a marker of
bacterial sepsis, but the role of invasive fungal infection
(IFI) is controversial. In one study for proven or probable
IFI,12 PCT was elevated in fewer than half of invasive
candidiasis episodes in the early phase of IFI, and the
sensitivity and specificity rates are low. The erythrocyte
sedimentation rate (ESR) is a biomarker of high sensitivityand low specificity for tissue inflammation. There are many
factors which elevate the ESR, including various infectious
diseases, hematologic and neoplastic diseases, collagen
diseases, renal diseases, and miscellaneous diseases.13,14
No previous report about applying ESR in AV graft
Candida infection was reported. Our case had ESRD, which
may interfere with the ESR value. The above revealed the
limited roles of PCT and ESR in the management of AV graft
Candida infection.
Experience from cases 4e6 revealed that removal of the
AV graft is crucial when relapse of Candida AV graft infec-
tion occurred. C. glabrata is more prone to be resistant to
azole drugs when compared to C. albicans and C. tropica-
lis,15 although there is no comparison of the susceptibility
results between the species of Candida isolates from the AV
graft. Our C. glabrata AV graft infection case demonstrated
that Candida species in fungal AV fistula infection is not
limited to azole susceptible species, like C. albicans and C.
tropicalis (Table 1). For AV graft infection caused by
Candida species not fully susceptible to azole class drugs,
our case report revealed that echinocandins could be
effective.
In conclusion, we report the first case of C. glabrata AV
graft infection that was treated effectively with echino-
candins, after the AV graft was removed. The outcome of
our case, and patients from the literature review, suggest
that removal of the infected graft is important for treat-
ment success of AV graft Candida infection.
Consent
For the patient who died, her son signed a written consent
to agree to the academic report of his mother’s Candida
infection.
Conflicts of interest
All authors declare no financial conflict of interest.
Acknowledgments
H.L.H., W.T.W. and P.L.L. prepared the manuscript. Y.H.C.
and P.L.L. provided laboratory support. C.Y.L. and Y.T.C.
cared for the patients and advised on the clinical aspects of
the case report. All authors read and approved the final
version of the manuscript.
References
1. Jorda`-Marcos R, A´lvarez-Lerma F, Jurado M, Palomar M, Nolla-
Salas J, Leon MA, et al. Risk factors for candidaemia in criti-
cally ill patients: a prospective surveillance study. Mycoses
2007;50:302e10.
2. Kojic EM, Darouiche RO. Candida infections of medical devices.
Clin Microbiol Rev 2004;17:255e67.
3. Nassar GM, Ayus JC. Infectious complications of the hemodi-
alysis access. Kidney Int 2001;60:1e13.
4. Berman DS, Diamond GR, Rubin DS, El-Sadr W, Simberkoff MS.
Candida albicans infection of an arteriovenous graft used for
hemodialysis. JAMA 1987;258:614.
304 H.-L. Huang et al.5. Kathresal A, Biundo J, Blais CM, Morse S, Reisin E. A rare case
of Candida arthritis in a hemodialysis patient. Am J Med Sci
2008;336:437.
6. Nguyen MH, Yu VL, Morris AJ. Candida infection of the arte-
riovenous fistula used for hemodialysis. Am J Kidney Dis 1996;
27:596e8.
7. Clinical and Laboratory Standards Institute. Reference
method for broth dilution antifungal susceptibility testing
of yeasts. 3rd informational supplement, M27-S3. Wayne, PA.
USA: Clinical and Laboratory Standards Institute; 2008.
8. Quarles L, Rutsky E, Rostand S. Staphylococcus aureus
bacteremia in patients on chronic hemodialysis. Am J Kidney
Dis 1985;6:412.
9. Anderson JE, Chang ASY, Anstadt MP. Polytetrafluoroethylene
hemoaccess site infections. ASAIO Journal 2000;46:S18.
10. Schild AF, Perez E, Gillaspie E, Seaver C, Livingstone J,
Thibonnier A. Arteriovenous fistulae vs. arteriovenous grafts: aretrospective review of 1,700 consecutive vascular access
cases. J Vasc Access 2008;9:231.
11. Foundation NK. Clinical practice guidelines for vascular access.
Am J Kidney Dis 2006;48:S176e247.
12. Dornbusch H, Strenger V, Kerbl R, Lackner H, Schwinger W,
Sovinz P, et al. Procalcitoninea marker of invasive fungal
infection? Support Care Cancer 2005;13:343e6.
13. Bathon J, Graves J, Jens P, Hamrick R, Mayes M. The erythro-
cyte sedimentation rate in end-stage renal failure. Am J Kid-
ney Dis 1987;10:34.
14. Hardeman MR. Erythrocyte sedimentation rate. Clin Hemor-
heol Microcirc 2007;36:263.
15. Lyon GM, Karatela S, Sunay S, Adiri Y. Antifungal susceptibility
testing of Candida isolates from the Candida surveillance
study. J Clin Microbiol 2010;48:1270e5.
